

K080287

pg 1 of 2

510k Summary

JUL - 3 2008

This 510K Summary is submitted in accordance with 21 CFR 807.92 as amended in the Final Rule published in the Federal Register Vol. 59, No. 239, 12-14-94, p. 64295.

Company information:

Name: AngioDynamics, Inc.
Address: 603 Queensbury Avenue
Queensbury, New York 12804
Telephone Number: 518-798-1215
Contact Person: Teri Juckett
Date Submitted: February 1, 2008

Device information:

Name of Device: Bipolar Electrode
Common Name: Tissue Ablation Accessory
Classification: Electrosurgical Cutting and Coagulation Device

Predicate Device information:

Oncobionic System, K060054
Rita Medical UniBlate Electrosurgical Device, K070101

Device Description:

The Oncobionic Bipolar Electrode combines two electrodes into one device. The combined electrodes operate to deliver energy from the previously cleared Oncobionic System (K060054). The Oncobionic Bipolar electrode applies a LEDC pulse or series of pulses between two electrodes to cause an ablation effect to occur.

510k Summary Continued

Intended Use:

The Oncobionic Bipolar Electrode is intended to be used only with the Oncobionic System and is intended for surgical ablation of soft tissue.

Comparison to Predicate Device:

The Oncobionic Bipolar Electrode created equivalent tissue ablation to the Rita Medical UniBlate Electrosurgical Device. The Oncobionic System is as safe and effective as the Oncobionic Electrode K060054. We have compared the efficacy of our device to the predicate devices and found them equivalent.

Performance Data:

We have included in-vivo test data, Attachment 1, which shows the Oncobionic Bipolar Electrode to be at least as safe and effective as the predicate devices. This test shows that the Oncobionic Bipolar Electrode is substantially equivalent to the predicate devices for creating ablation zones in soft tissue.

Sterilization Validation:

The Sterilization method used for the single use Oncobionic Bipolar Electrode is Ethylene Oxide Sterilization.

Software Validation:

The Oncobionic Bipolar Electrode does not use software.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AngioDynamics, Inc.
% Mr. Teri Juckett
602 Queensbury Avenue
Queensbury, New York 12804

JUL - 3 2008

Re: K080287

Trade/Device Name: Oncobionic Bipolar Electrode
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: II
Product Code: GEI
Dated: June 30, 2008
Received: June 30, 2008

Dear Mr. Juckett:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Teri Juckett

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K080287

pg 1 of 1

Indications for Use

510(k) Number:

Device Name: Oncobionic Bipolar Electrode

Indications for Use: The Oncobionic Bipolar Electrode is intended to be used only with the Oncobionic System and is indicated for surgical ablation of soft tissue.


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K080287